Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pfizer Inc. (PFE)

49.57   0.36 (0.73%) 11-28 16:03
Open: 49.18 Pre. Close: 49.21
High: 49.74 Low: 49.06
Volume: 19,410,572 Market Cap: 278,252(M)

Technical analysis

as of: 2022-11-28 4:42:16 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 58.18     One year: 67.96
Support: Support1: 46.77    Support2: 44.88
Resistance: Resistance1: 49.81    Resistance2: 58.18
Pivot: 48.23
Moving Average: MA(5): 48.98     MA(20): 47.94
MA(100): 47.37     MA(250): 50.23
MACD: MACD(12,26): 0.9     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 82.9     %D(3): 77.2
RSI: RSI(14): 65.1
52-week: High: 61.7  Low: 41.45
Average Vol(K): 3-Month: 19,705 (K)  10-Days: 16,257 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PFE ] has closed below upper band by 10.1%. Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 49.78 - 49.99 49.99 - 50.18
Low: 48.55 - 48.78 48.78 - 48.99
Close: 49.21 - 49.56 49.56 - 49.9

Company Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Headline News

Mon, 28 Nov 2022
PFE: 1 High-Dividend Stock to Add to Your Portfolio if You Haven't Already -

Mon, 21 Nov 2022
PFE: 2 Strong Stocks to Consider Buying This November -

Mon, 21 Nov 2022
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters - Nasdaq

Thu, 17 Nov 2022
What is Wall Street's Target Price for Pfizer Inc. (PFE) Stock Thursday? - InvestorsObserver

Mon, 14 Nov 2022
PFE Makes Bullish Cross Above Critical Moving Average - Nasdaq

Mon, 14 Nov 2022
Pfizer Stock: Get Ready To Go On Board (NYSE:PFE) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 5,610 (M)
Shares Float 5,610 (M)
% Held by Insiders 0 (%)
% Held by Institutions 70 (%)
Shares Short 62,510 (K)
Shares Short P.Month 63,890 (K)

Stock Financials

EPS 1.71
EPS Est Next Qtl 0.56
EPS Est This Year 2.55
EPS Est Next Year 2.75
Book Value (p.s.) 11.35
Profit Margin (%) 28.9
Operating Margin (%) 38
Return on Assets (ttm) 13.1
Return on Equity (ttm) 37.4
Qtrly Rev. Growth 46.7
Gross Profit (p.s.) 9.02
Sales Per Share 18.05
EBITDA (p.s.) 7.75
Qtrly Earnings Growth 77.4
Operating Cash Flow 31,450 (M)
Levered Free Cash Flow 29,060 (M)

Stock Valuations

PE Ratio 28.98
PEG Ratio 0
Price to Book value 4.36
Price to Sales 2.74
Price to Cash Flow 8.84

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2022-03-03
Ex-Dividend Date 2022-01-26
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.